Introduction {#Sec1}
============

Invasive aspergillosis (IA) is a fungal infection that primarily affects immunocompromised individuals. In 2013, a total of 2990 hospitalizations with a primary diagnosis of IA, and 14,470 hospitalizations with either a primary or secondary diagnosis of IA, occurred in the USA \[[@CR1]\]. Risk factors for IA include the presence of hematological malignancies, hematopoietic stem cell or solid organ transplant, severe and/or prolonged neutropenia, prolonged and/or high-dose immunosuppressive therapy, and chemotherapy \[[@CR2]\]. The majority of cases of IA are encountered in patients with hematological malignancies and bone marrow transplant patients (43.0--68.0%), with the remainder of cases occurring in solid organ transplant recipients (13.0--17.0%) and other immunocompromised hosts (10.0--15.0%) \[[@CR3], [@CR4]\].

IA is a serious, life-threatening condition. The reported 1-year overall survival rate following a diagnosis of IA among bone marrow transplant patients ranges from 10.0 to 40.0% in the literature \[[@CR5], [@CR6]\]. Among critically ill patients admitted to an intensive care unit with proven IA, overall survival rates at 84 days after diagnosis of IA have been reported to be 21.0% \[[@CR7]\]. A 2010 analysis of a national hospital administrative database found that the median length of hospitalization among patients diagnosed with IA was 18--26 days (depending on whether IA was a primary or secondary diagnosis) \[[@CR8]\]. During this time, hospitals incurred a median cost between \$32,465 and \$68,008 (2006 USD), with antifungal medications accounting for 6.0--10.2% of those costs \[[@CR8]\]. A 2009 analysis of data from the 2003 Nationwide Inpatient Sample concluded that the length of hospitalization for immunocompromised patients with IA was 1.8--12.4 times higher than the length of hospitalization of similarly high-risk immunocompromised patients without IA and the median hospital charges were 2.3--12.7 times higher (depending on diagnosis-related group) \[[@CR9]\]. The annual total cost of IA in the USA, including hospitalizations, subsequent home healthcare, and outpatient medications, was estimated to be \$674 million in 1998 \[[@CR10]\], the equivalent of \$1.3 billion today.

Current treatment guidelines, published before FDA approval of isavuconazonium sulfate, recommend several antifungal agents for the treatment of IA, including voriconazole, amphotericin B and its lipid formulations, itraconazole, posaconazole, and caspofungin \[[@CR11], [@CR12]\]. Voriconazole, an antifungal triazole that inhibits fungal respiration and cell membrane function, is currently the preferred agent for first-line treatment of IA, both from a clinical \[[@CR11]\] and an economic perspective \[[@CR13], [@CR14]\]. Amphotericin B has a less favorable safety profile \[[@CR15]\] and lower efficacy \[[@CR15]\] compared to voriconazole, and it is recommended for patients who cannot be treated with voriconazole \[[@CR11]\]. Other available agents offer limited efficacy benefits compared to voriconazole and therefore are recommended as salvage therapy agents after voriconazole or amphotericin B treatment \[[@CR11]\]. A literature review conducted by Krueger and Nelson identified 10 pharmacoeconomic analyses in six different countries comparing voriconazole to other options for the treatment of IA, and all these analyses concluded that voriconazole was the most cost-effective therapy compared to other treatment options discussed above \[[@CR13]\]. Another advantage of voriconazole is that it can be administered both orally and intravenously (IV). Voriconazole does present several possible disadvantages: possible toxicity of the IV formulation in patients with renal failure (due to required co-administration with solubility additive sulfobutylether-β-cyclodextrin) \[[@CR11], [@CR14]\], a twice daily dosing schedule of the oral medication because of relatively rapid metabolization \[[@CR14]\], and a known risk of drug--drug interactions (due to its effect on the CYP2C19, CYP2C9, and CYP3A4 metabolic pathways) \[[@CR11], [@CR14]\].

Isavuconazonium sulfate, a novel triazole and prodrug of isavuconazole, received FDA approval for the treatment of IA and invasive mucormycosis in March 2015 \[[@CR16]\]. The approval was granted on the basis of data from the SECURE clinical trial (NCT00412893), which showed that isavuconazole has comparable efficacy with voriconazole \[[@CR17]\]. All-cause mortality at day 42 (the SECURE trial primary endpoint) was similar in both treatment groups (18.6% in the isavuconazole-treated group and 20.2% in the voriconazole-treated group). Overall adverse event (AE) rates were also similar (96.1% of isavuconazole-treated patients and 98.5% of voriconazole-treated patients experienced at least one treatment-emergent AE) \[[@CR17]\]. However, statistically significant differences were observed in eye disorders, hepatobiliary disorders, and skin disorders, with isavuconazole-treated patients having significantly lower rates of these events \[[@CR17]\]. Similar to voriconazole, isavuconazole is also available in both oral and IV formulations. Its IV formulation, however, does not require solubility additive sulfobutylether-β-cyclodextrin, which has been associated with potential nephrotoxicity in the voriconazole IV formulation \[[@CR18]\]. Oral isavuconazole has a longer half-life than oral voriconazole, allowing for once daily dosing. In addition, the metabolism of isavuconazole is limited to the CYP3A4 and CYP3A5 pathway \[[@CR18]\].

In order to determine the optimal treatment option, it is important to thoroughly evaluate new therapies against existing standards by comparing efficacy, safety, costs, and cost-effectiveness. No existing study compares the costs and cost-effectiveness of isavuconazole vs. voriconazole. To fill this gap, the current study has been conducted to estimate the total cost per treated patient and evaluate the cost-effectiveness of isavuconazole vs. voriconazole from a US hospital perspective.

Methods {#Sec2}
=======

Model Overview, Perspective, and Population {#Sec3}
-------------------------------------------

A cost-effectiveness decision tree model was developed in Microsoft Excel 2010 (Fig. [1](#Fig1){ref-type="fig"}). The target population included patients with proven, probable, or possible invasive fungal disease caused by the *Aspergillus* species or other filamentous fungi (reflecting the SECURE trial population) \[[@CR17]\]. Two treatments, isavuconazole and voriconazole, were compared. The model estimated the total cost per IA patient treated with each product, with total cost defined as the sum of drug, AE, and hospital stay costs. Incremental cost per death avoided and the incremental cost per additional responder comparing isavuconazole to voriconazole were also estimated. The model was developed from a US hospital perspective, in which only direct costs incurred during the hospitalization were considered, with a time horizon of one hospital stay (including readmissions occurring within 30 days of the original discharge). Readmission within 30 days was considered given that it was a prespecified endpoint in the clinical trial. Because this time horizon is less than 1 year, discounting of costs and effectiveness measures was not necessary. This article does not contain any new studies with human or animal subjects performed by any of the authors. The model relied only on the summary statistics from the SECURE trial (ClinicalTrials.gov identifier NCT00412893) and patient level data was not used. Institutional review board (IRB) review was not needed.Fig. 1Clinical progression of patients through the model. *IA* invasive aspergillosis. Hospitalized patients with IA would enter the model and they could receive either isavuconazole or voriconazole. While receiving treatments, patients could experience adverse events related to hepatobiliary, eye, and skin disorders. Patients were evaluated for survival and clinical response at the end of model cycle. Length of stay and likelihood of readmission (not depicted here) are also considered in the calculation of healthcare costs

Efficacy and Safety Inputs {#Sec4}
--------------------------

Efficacy inputs, mortality and clinical response, for both treatment arms were extracted from the SECURE trial (Table [1](#Tab1){ref-type="table"}) \[[@CR17]\]. Mortality was the primary efficacy endpoint and clinical response was the secondary endpoint in the SECURE trial. As was previously described, all-cause mortality at day 42 was 18.6% for isavuconazole-treated patients and 20.2% for voriconazole-treated patients \[adjusted difference = −1.0%, 95% CI (−7.8, 5.7%)\] \[[@CR17]\]. Clinical response rates were 62.0% and 60.3%, respectively \[adjusted difference = 0.4%, 95% CI (−10.64, 11.53%)\] \[[@CR17]\]. The differences in these two outcomes were not statistically significant. The median length of stay of the initial hospitalization was 13 days for isavuconazole-treated patients and 15 days for voriconazole-treated patients \[[@CR19]\]. Following discharge from the initial hospitalization, 18.3% of isavuconazole-treated patients and 24.4% of voriconazole-treated patients had a readmission within 30 days \[adjusted difference = −6.0%, 95% CI (−13.3, 1.3%)\]. This difference was not statistically significant \[[@CR19]\]. The median length of stay for readmissions (6 days) was obtained from an analysis of the Premier database of inpatients with a diagnosis of IA and who had a readmission \[[@CR20]\]; in the absence of other information, it was assumed to be equal across treatment arms.Table 1Model inputs: efficacy, dosing schedule, and costsDefinitionBase case valueSource/notesEfficacyISAVVORIMortality rate18.6%20.2%SECURE trial \[[@CR17]\]; measured at day 42 on the basis of the intent to treat (ITT) populationClinical response rate62.0%60.3%SECURE trial \[[@CR17]\]; measured at end of treatment on the basis of the modified ITT populationInitial hospital length of stay, days13.0 days15.0 daysSECURE trial \[[@CR19]\]30-day readmission rate18.3%24.4%SECURE trial \[[@CR19]\]Readmission length of stay, days6.0 daysEstimated from an administrative database study of hospitalized patients with IA \[[@CR20]\]Dosing scheduleDoseFrequency (per day) ISAVProduct label \[[@CR16], [@CR22]\]  Day 1: IV infusion372 mg3  Day 2: IV infusion372 mg3  Day 3 to end of treatment  IV infusion372 mg1  Oral (tablet)372 mg1 VORI  Day 1: IV infusion6 mg/kg2  Day 2: IV infusion4 mg/kg2  Day 3 to end of treatment  IV infusion4 mg/kg2  Oral (tablet)200 mg2Treatment duration within hospital, daysIV infusionOralISAV8.14.9SECURE clinical trial data \[[@CR17]\]VORI8.96.1Drug cost (WAC)Cost per unitISAVReadyPrice^®^ (Thomson) \[[@CR23]\]  IV infusion (372 mg)\$238.50  Oral (tablet) (186 mg)\$70.00VORI (generic)  IV infusion (200 mg)\$122.07  Oral (tablet) (200 mg)\$35.05Hospitalization cost^a^ Per diem cost of hospitalization related to IA\$2898.31HCUP NIS \[[@CR1]\]*ISAV* isavuconazole, *VORI* voriconazole, *IV* intravenous, *HCUP NIS* Healthcare Cost and Utilization Project National Inpatient Sample^a^Inflated to 2015 USD

The model considered grade III and IV AEs whose overall incidence significantly differed between isavuconazole- and voriconazole-treated patients in the SECURE trial, i.e., eye disorders, hepatobiliary disorders, and skin disorders (individually described in ESM Appendix 1) \[[@CR21]\].

Dosing Frequency and Duration Inputs {#Sec5}
------------------------------------

The dosing schedules for both voriconazole and isavuconazole were based on the doses administered in the SECURE trial \[[@CR17]\], and they are consistent with their respective product labels \[[@CR16], [@CR22]\]. The current model assumed there was no vial wastage. Both isavuconazole and voriconazole were initiated as an IV infusion and could subsequently be converted to an oral formulation as early as day 3, on the basis of physician evaluation. IV voriconazole was dosed on the basis of patients' weight, while administration of oral voriconazole, IV and oral isavuconazole was based on fixed dosing. The model assumed an average patient weight of 75 kg to estimate costs of IV voriconazole, which was the midpoint of the average weight of 82 kg of adults older than 20 years of age in the USA and the mean weight of 69 kg in the SECURE trial \[[@CR21]\]. Details regarding the dosing of each treatment arm can be found in Table [1](#Tab1){ref-type="table"}. The total duration of isavuconazole treatment (including IV and oral formulations) reported in the SECURE trial was 47.0 days on average, 8.1 days of which were IV treatment \[[@CR17]\]. Only drugs administered within the hospital were considered; thus, the model included the costs of 8.1 days of IV and 4.9 days (13.0--8.1 days) of oral isavuconazole treatment. The total duration of voriconazole treatment was 46.4 days in the SECURE trial, 8.9 days of which were IV treatment \[[@CR17]\]. The model considered voriconazole treatment as 8.9 days of IV and 6.1 days (15.0--8.9 days) of oral dosing.

Cost Inputs {#Sec6}
-----------

Prices of isavuconazole and voriconazole were estimated on the basis of the wholesale acquisition costs (WACs), obtained from ReadyPrice^®^ (Thomson) (Table [1](#Tab1){ref-type="table"}) \[[@CR23]\]. Given that generic voriconazole is already available and with a lower price, the price of generic voriconazole was used. The price of 200 mg of voriconazole was \$122.07 and \$35.05 for the IV and oral formulations, respectively. The price of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) was \$238.50 and \$70.00 for the IV and oral formulations, respectively.

The per diem cost of hospitalization due to IA was estimated at \$2898.31, using the 2013 HCUP Nationwide Inpatient Sample (NIS), a publicly available database created and maintained by the Agency for Healthcare Research and Quality (AHRQ) \[[@CR1]\]. The same per diem cost of hospitalization was assumed for initial hospitalizations and readmissions (Table [1](#Tab1){ref-type="table"}). All costs were inflated to 2015 USD \[[@CR24]\].

The costs of managing AEs were estimated using published literature \[[@CR25]--[@CR37]\]. For acute AEs, the cost of managing the entire AE episode was included and this cost was assumed to be equal among the treatment arms. For AEs which could last beyond the initial hospitalization, the cost per AE reported in literature (typically reported as an annual cost) was prorated on the basis of the length of initial hospital stay (i.e., 13 days for isavuconazole and 15 days for voriconazole) for each treatment arm. Prorating AEs this way makes the assumption that those AEs begin on the first day of IA therapy. This assumption is used given the lack of detailed information on time of AE onset and the fact that costs of AE do not have a significant impact on the model's results. When no literature was available, the cost of each AE was assumed to be the cost of an inpatient consultation of moderate complexity. In the case of hepatobiliary disorders, the cost of a liver function panel was also included.

Deterministic and Probabilistic Sensitivity Analyses (DSA and PSA) {#Sec7}
------------------------------------------------------------------

Deterministic sensitivity analysis (DSA) was carried out by increasing and decreasing one parameter at a time while maintaining the rest of the inputs at the base case value. Treatment duration, length of hospitalization (length of stay), readmission rate, per diem cost of hospitalization, drug costs, costs of AE treatment, clinical response rates, and mortality rates were all varied in the DSA to evaluate their impact. In addition, a sensitivity analysis assuming that a US payer perspective was included. This payer perspective included drug and AE costs throughout the total duration of isavuconazole and voriconazole treatment. The total duration was reported by Horn et al. (including inpatient and outpatient) \[[@CR19]\]. Another sensitivity analysis assumed equal hospital length of stay, mortality, and clinical response rate among isavuconazole- and voriconazole-treated patients. For this analysis, the average of each input for isavuconazole and voriconazole was used for both treatments. Sensitivity analyses were also conducted by changing only the inputs of isavuconazole to make it less favorable than voriconazole. The parameter inputs were varied on the basis of either the confidence interval, if available, or a predefined percentage of the base case value (ESM Appendix 2).

Probabilistic sensitivity analysis (PSA) was carried out by assuming parametric distributions for each input parameter and resampling each parameter simultaneously from their respective distributions to re-estimate model outputs (ESM Appendix 2). Treatment duration was assumed to follow normal distributions, and mortality and clinical response rates were assumed to follow beta distributions. The standard errors of these parameters were estimated from the SECURE trial. The initial hospitalization length of stay follows a uniform distribution, with the min and max specified as ∓25.0% of the base case value. The per diem cost of hospitalization and the costs of managing AEs were assumed to follow gamma distributions, with standard errors assumed to be equal to one quarter of their respective means. Five-thousand random draws were conducted. PSA was conducted for all three outcomes: incremental cost per patient, incremental cost per death avoided, and incremental cost per clinical responder. For the incremental cost per patient, the results of the PSA were summarized in a cost-minimization acceptability curve based on incremental cost per patient. For the incremental cost per death avoided and the incremental cost per clinical responder, cost-effectiveness acceptability curves were plotted on the basis of net monetary benefit (NMB) values, which were estimated on the basis of willingness to pay threshold × incremental benefit − incremental costs.

Results {#Sec8}
=======

The model estimated the total costs per treated patient receiving isavuconazole and voriconazole, the incremental cost per patient treated with isavuconazole vs. voriconazole, the incremental cost per death avoided (isavuconazole vs. voriconazole), and the incremental cost per clinical responder (isavuconazole vs. voriconazole).

Isavuconazole was associated with a lower total cost per patient compared to voriconazole (\$44,748.38 vs. \$52,166.16). This was a result of lower drug costs (\$3571.85 vs. \$3869.99), lower costs of AEs (\$317.42 vs. \$576.74), lower costs of initial hospitalization (\$37,678.04 vs. \$43,474.66), and lower costs of hospital readmissions (\$3181.07 vs. \$4244.77) among isavuconazole-treated patients than voriconazole-treated patients. Isavuconazole was dominant (lower costs and greater health benefits) against voriconazole with respect to incremental cost per death avoided and incremental cost per clinical responder (Table [2](#Tab2){ref-type="table"}).Table 2Base case results: costs and cost-effectiveness of ISAV vs. VORIParameterISAVVORITotal cost per patient\$44,748.38\$52,166.16 Total drug cost\$3571.85\$3869.99 AE cost\$317.42\$576.74 Initial hospitalization cost\$37,678.04\$43,474.66 Hospital readmission cost\$3181.07\$4244.77Incremental cost per death avoidedISAV is dominant over VORI^a^Incremental cost per additional clinical responderISAV is dominant over VORI^a^*ISAV* isavuconazole, *VORI* voriconazole, *AE* adverse event^a^"Dominant" indicates greater health benefits (survival, clinical response) and lower cost

Isavuconazole was predicted to be associated with lower total cost per patient than voriconazole in each DSA except for when the initial hospitalization length was increased by 25.0% for isavuconazole-treated patients and left unchanged for voriconazole-treated patients (Table [3](#Tab3){ref-type="table"}). All other DSAs estimated a lower cost for isavuconazole than voriconazole, ranging from \$1411.05 to \$17,292.29 savings per patient. The DSA using the US payer perspective (including both inpatient and outpatient drug and AE costs) estimated a cost saving of \$4849.26 for isavuconazole-treated patients, compared to voriconazole-treated patients. The DSA assuming equal LOS, mortality, and clinical response for isavuconazole and voriconazole estimated a cost saving of \$1411.05 for isavuconazole.Table 3Deterministic sensitivity analysis results, ISAV vs. VORIParameterTotal cost per patientIncremental cost per death avoidedIncremental cost per clinical responderLow SA inputHigh SA inputLow SA inputHigh SA inputLow SA inputHigh SA inputChanging the inputs for both ISAV and VORI Treatment duration (IV)−\$7173.91−\$7661.64DominantDominantDominantDominant Treatment duration (oral)−\$7703.00−\$7132.55DominantDominantDominantDominant Total treatment duration−\$7522.57−\$7312.98DominantDominantDominantDominant Initial hospital length of stay (±25.0%)−\$6161.21−\$8674.34DominantDominantDominantDominant Initial hospital length of stay (mean values)−\$2200.00DominantDominant Readmission length of stay−\$7151.85−\$7683.70DominantDominantDominantDominant Readmission rate−\$7327.91−\$7484.42DominantDominantDominantDominant Per diem cost of hospitalization−\$5702.70−\$9132.86DominantDominantDominantDominant Total cost of AEs−\$7352.95−\$7482.61DominantDominantDominantDominant Drug prices (IV and oral)−\$7343.24−\$7492.31DominantDominantDominantDominant Payer perspective−\$4833.26DominantDominant Equal initial length of stay, mortality rate, and clinical response rate−\$1411.05---- Mortality rate----DominantDominantDominantDominant Clinical response rate----DominantDominantDominantDominantChanging the inputs for ISAV only Initial hospital length of stay−\$17,295.94\$2460.39Dominant\$158,459.35Dominant\$143,398.88 Readmission rate−\$8216.44−\$6477.45DominantDominantDominantDominant Mortality rate----Dominant\$198,126.42---- Clinical response rate--------\$106,054.92Dominant*ISAV* isavuconazole, *VORI* voriconazole, *IV* intravenous, *AE* adverse event

DSAs for incremental cost per death avoided and incremental cost per clinical responder showed isavuconazole was dominating against voriconazole in all but two cases: when the initial hospitalization length increased by 25.0% for isavuconazole-treated patients but remained unchanged for voriconazole-treated patients, and when the relevant efficacy outcome, i.e., 42-day mortality rate or clinical response rate, changed unfavorably for isavuconazole but remained unchanged for voriconazole (making isavuconazole worse than voriconazole).

In all PSA simulations of the total cost per patient, the incremental cost per patient (comparing isavuconazole vs. voriconazole) was less than \$50,000 (ESM Appendix 3). In 80.2% of those simulations, isavuconazole was associated with a lower total cost per patient than voriconazole. At a willingness to pay (WTP) of \$50,000 per death avoided, 82.4% of simulations found isavuconazole to be cost-effective compared to voriconazole on the basis of NMB values (ESM Appendix 3). Similar results were seen when the cost per clinical responder was considered. At a WTP of \$50,000 per clinical responder, 81.8% of simulations indicated isavuconazole to be cost-effective compared to voriconazole on the basis of NMB values (ESM Appendix 3).

Discussion {#Sec9}
==========

The current standard of care for the treatment of IA is voriconazole. However, isavuconazole, a novel triazole, was recently introduced in the USA for the treatment of IA. An appealing alternative treatment option, isavuconazole has comparable efficacy as voriconazole and isavuconazole is well tolerated compared with voriconazole, with fewer drug-related adverse events. Findings from this economic evaluation show that isavuconazole is associated with lower costs per treated patient and is a cost-effective option compared to voriconazole for the treatment of IA. Isavuconazole dominates voriconazole in terms of incremental cost per additional death avoided and per additional clinical responder.

In our analyses, the difference in the cost of hospitalization was the main driver of the difference in total costs between isavuconazole and voriconazole, contributing to 92.0% of the difference in total cost. Isavuconazole-treated patients were associated with a shorter duration of initial stay and lower rate of readmission compared to voriconazole-treated patients, leading to a lower hospitalization cost. Isavuconazole's shorter duration of treatment and fewer doses per day from day 3 onward led to lower isavuconazole drug cost, compared to voriconazole, despite a higher drug cost per day. Isavuconazole's lower incidence rates of AEs also translated into additional cost saving. As a result, the use of isavuconazole may lead to a cost saving of \$7417.78 per patient compared to voriconazole.

The study results were robust. In most sensitivity analyses, isavuconazole was associated with lower cost and greater health benefits (dominating scenario) compared to voriconazole. Only in situations where the initial length of hospital stay, mortality rate, and clinical response rate were made wholly unfavorable for isavuconazole (while maintaining voriconazole inputs) was isavuconazole no longer associated with cost savings or dominance, compared to voriconazole. Given the fact that isavuconazole is associated with numerically shorter length of stay, lower mortality, and higher response rates compared to voriconazole in the SECURE trial, these worst-case scenarios seem highly unlikely \[[@CR17]\]. Even when LOS, mortality rate, and clinical response rate were assumed to be equal, isavuconazole was still associated with a lower cost per patient owing to the lower rate of readmission and associated readmission costs. In about 80.0% of the PSA simulations, isavuconazole is less costly than voriconazole; in the majority of the simulations (approx. 82% of cases), isavuconazole is also more cost-effective than voriconazole at a WTP of \$50,000 per additional outcome.

No prior studies have compared the cost-effectiveness of isavuconazole vs. voriconazole in the treatment of IA; however, there are multiple studies comparing voriconazole to other IA treatments \[[@CR13], [@CR38]\]. Those studies have concluded that voriconazole is the preferred therapy for IA in terms of cost-effectiveness. The current study utilized a similar methodology as these prior studies and found that isavuconazole is associated with a lower cost per patient and dominates voriconazole in cost-effectiveness analysis for the treatment of IA in the hospital setting.

The results of this study demonstrate that isavuconazole is a valuable addition to the IA armamentarium. The efficacy of isavuconazole is similar to that of voriconazole. Isavuconazole, however, is associated with a lower total cost per patient and is cost-effective compared to voriconazole. In the USA, where the cost of healthcare is steadily increasing, cost-effectiveness analyses are increasingly important in helping healthcare decision-makers to evaluate different reimbursement decisions and in helping physicians and patients make the optimal selection of therapy for a given condition. Given that IA imposes a substantial economic and clinical burden on society \[[@CR8], [@CR9]\], optimizing the treatment of IA by evaluating the cost-effectiveness of alternative treatment options could help improve the care and reduce the overall healthcare spending. Evidence from the current study could support payers and physicians in the process of therapy selection for the treatment of IA by providing valuable information for effective decision-making.

Limitations {#Sec10}
-----------

This economic evaluation is subject to several limitations. First, the model did not consider costs of treating any underlying conditions. The costs associated with treating underlying diseases can be substantial and may vary greatly by disease condition. There is, however, no evidence that treatment with isavuconazole or voriconazole could impact the costs of underlying disease conditions. Second, in order to make an informed comparison of first-line treatment with isavuconazole vs. voriconazole, no subsequent therapy was considered. The results of the SECURE trial indicated that the clinical response rate was numerically higher (not statistically significant) with isavuconazole than with voriconazole treatment; therefore, not including subsequent treatment is expected to be conservative against the isavuconazole arm, where a lower proportion of patients might receive subsequent therapy and incur associated costs. Additionally, although clinical trials are the gold standard for determining the comparative efficacy of alternative treatments, they often have restrictive inclusion and exclusion criteria and thus patients in the trial may lack the heterogeneity presented in real-world clinical practice. Finally, as the perspective of this study was that of a US hospital (and US payer, in sensitivity analysis), our results may not be generalizable to other countries with different healthcare systems, practices, and prices.

Conclusions {#Sec11}
===========

This economic evaluation shows that isavuconazole may be a cost-effective option compared to voriconazole for the treatment of IA in the hospital setting. Isavuconazole was associated with a lower total cost per patient and dominated voriconazole in terms of incremental costs per additional death avoided and cost per additional clinical responder.
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